Abstract
According to the investigation in a large cohort, we reported for the first time the prognostic potential of the salivary DJ-1 as a biomarker for evaluating nigrostriatal dopaminergic function in Parkinson's Disease (PD). While salivary DJ-1 cannot yet be used to diagnose PD in its early stages, it shows significant promise as a non-invasive progression marker that increases as the disease reaches advanced stages.
Introduction
Parkinson’s Disease (PD) is notoriously difficult to track objectively. By the time a patient shows classic motor symptoms, they have often already lost approximately 70% of the dopaminergic neurons in their substantia nigra. Currently, clinicians rely on subjective rating scales, such as the Unified Parkinson's Disease Rating Scale (UPDRS), to monitor patients, which can lead to inconsistent assessments.
While brain imaging techniques like SPECT and PET can visualize this neuronal loss, they are expensive and involve radiation exposure. Consequently, researchers are searching for "biomarkers"—measurable substances in bodily fluids—that mirror pathological changes in the brain. While cerebrospinal fluid (CSF) is a reliable source, it requires an invasive spinal tap. Saliva, conversely, is easy to collect and non-invasive, making it an ideal medium for long-term monitoring. This study investigates whether the protein DJ-1, known for its role in managing cellular oxidative stress, could serve as a reliable progression marker for PD.
Methodology
The study was conducted in two primary phases:
- Pilot Imaging Correlation: In a group of 74 PD patients and 12 controls, the team performed SPECT imaging using the radiotracer $^{99m}Tc$-TRODAT-1. This tracer binds to dopamine transporters (DAT), providing a "gold standard" measurement of functional dopamine terminals in the caudate and putamen.
- Large Cohort Validation: The study was expanded to 376 volunteers (285 PD patients and 91 healthy controls) to evaluate how salivary DJ-1 levels changed across different disease stages (Hoehn & Yahr stages 1-4) and clinical subtypes (Tremor-dominant, Akinetic-rigid, or Mixed).
To measure the minute concentrations of DJ-1 in saliva, researchers utilized a Luminex assay, a bead-based immunoassay that offers higher sensitivity and quantification than traditional methods.
Results
Imaging Correlation and the Putamen Connection
A critical finding of the study was the relationship between salivary protein levels and brain degeneration. Salivary DJ-1 levels showed a statistically significant correlation with DAT uptake in the putamen ($p = 0.026$), a brain region heavily affected by PD. Interestingly, this correlation was not observed in the caudate, suggesting that salivary DJ-1 specifically reflects the pathological changes occurring in the putamen.
Progression and Disease Staging
The data indicates that salivary DJ-1 functions as a "progression marker" rather than a diagnostic tool. DJ-1 levels were not significantly different between healthy controls and early-stage PD patients. However, levels were significantly higher in patients at Hoehn & Yahr (H&Y) stage 4 compared to stages 1-3 and healthy controls ($p = 0.005$). This suggests that as neurodegeneration accelerates and oxidative stress peaks in advanced stages, more DJ-1 is produced or leaked into the saliva.
Stability and Subtype Sensitivity
Salivary DJ-1 levels remained stable regardless of the patient's age, gender, or the specific Parkinson's medications they were taking (e.g., Levodopa). Regarding clinical subtypes, patients with the "Mixed" subtype exhibited lower DJ-1 levels than those with purely tremor or rigid symptoms, hinting at different biological mechanisms driving disease variations.
Discussion
While these results are promising, the study's cross-sectional design means it looked at different people at different stages. To confirm DJ-1 as a definitive progression indicator, longitudinal studies following the same patients over several years are required. Additionally, further research is needed to determine if salivary DJ-1 increases in other neurodegenerative diseases, which would clarify its specificity to PD. Finally, the exact mechanism by which DJ-1 enters the saliva—whether through secretion by salivary glands or leakage from the blood—remains to be elucidated.
Summary updated